Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3Fax-Neu5Ac (3-fluorinated N-acetylneuraminic acid) is a cell-permeable small molecule that acts as a global inhibitor of sialyltransferases. It is a fluorinated analog of sialic acid that, upon entry into the cell, is metabolically activated to CMP-3F-Neu5Ac. This metabolite acts as a potent competitive inhibitor of various sialyltransferases in the Golgi apparatus, effectively blocking the sialylation of glycoproteins and glycolipids on the cell surface. In oncology research, particularly in multiple myeloma, 3Fax-Neu5Ac is utilized to reduce hypersialylation, thereby disrupting the interaction between sialic acids and inhibitory Siglec receptors (such as Siglec-6) on immune cells. This blockade helps to reverse immune dysfunction, activate plasmacytoid dendritic cells (pDCs), and enhance T-cell-mediated anti-tumor activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3Fax-Neu5Ac.